SAN JUAN CAPISTRANO, Calif., Feb. 9 /PRNewswire-FirstCall/ -- Clarient, Inc. will report its 2005 fourth quarter and year-end results before the stock market opens on Tuesday, February 21, 2006. That same day management will host a conference call that will be broadcast live on the Internet at 11:30 a.m. (EST) to discuss results of operations.
Interested participants may access the live webcast on the Investor page under the Upcoming Events section on the Company’s website (www.clarientinc.com). Webcast listeners will be able to submit questions by emailing nathan@allencaron.com or clicking on the email address provided on the webcast page. Web participants are encouraged to go to the website at least 15 minutes prior to the start of the call to register and download and install any necessary audio software. For those unable to participate during the live broadcast, the webcast will be archived shortly after the call and will be available for one year.
About Clarient, Inc.
Clarient provides market leading technologies, services and expert support for the characterization, assessment and treatment of cancer, leading to more accurate diagnoses by pathologists, more confident treatment decisions by oncologists, a more efficient way to identify and develop pharmaceuticals and, ultimately, better outcomes for patients. A majority-owned subsidiary of Safeguard Scientifics, Inc., Clarient was formed in 1996 to develop and market the Automated Cellular Imaging System (ACIS). This digital imaging and assessment system allowed pathologists, for the first time, to obtain potentially more reliable, reproducible quantitative results for a broad range of slide-based diagnostic tests. In 2005, the ACIS and other leading diagnostic technologies such as flow cytometry and genetic testing were brought in-house to a state-of-the-art diagnostic laboratory and surrounded by a team of premier cancer specialists, forming the Clarient Diagnostic Services business. This facility and the Clarient team support the efforts of pathologists and the biopharmaceutical industry as a central resource for cancer diagnostics, disease interpretation, remote pathology, and contract research operations.
Clarient’s mission is to provide critical information to clinicians that will improve the quality and reduce the cost of patient care, and speed drug discovery. Many of the top clinical laboratories, hospitals, university medical centers and biopharmaceutical companies in the United States and Europe are currently using Clarient technology and services. Clarient and ACIS are registered trademarks of Clarient. For more information, visit www.clarientinc.com.
About Safeguard Scientifics, Inc.
Safeguard Scientifics, Inc. builds value in high-growth, revenue-stage information technology and life sciences businesses. Safeguard provides growth capital as well as a range of strategic, operating and management resources to our partner companies. The company participates in expansion financings, corporate carve-outs, management buyouts, recapitalizations, industry consolidations and early-stage financings. For more information about Safeguard, please visit www.safeguard.com.
Investors: Contact: Matt Clawson Roberta L. Smigel Allen & Caron, Inc. Corporate Communications (949) 474-4300 (949) 443-3355 matt@allencaron.cominvestorrelations@clarientinc.com
Clarient, Inc.
CONTACT: Investors, Matt Clawson of Allen & Caron, Inc., +1-949-474-4300,matt@allencaron.com, for Clarient, Inc.; or Roberta L. Smigel, CorporateCommunications of Clarient, Inc., +1-949-443-3355,investorrelations@clarientinc.com
